Abstract
The demand for recombinant proteins for analytic and therapeutic purposes is increasing; however, most currently used bacterial production systems accumulate the recombinant proteins in the intracellular space, which requires denaturating procedures for harvesting and functional testing. We here present a novel FimH-based expression system that enables display of fully functional eukaryotic proteins while preventing technical difficulties in translocating, folding, stabilizing and isolating the displayed proteins. As examples, Gaussia Luciferase (GLuc), epidermal growth factor (EGF), transforming growth factor-α (TGF-α) and epiregulin (EPRG) were expressed as FimH fusion proteins on the surface of E. coli bacteria.
The fusion proteins were functionally active and could be released from the bacterial surface by specific proteolytic cleavage into the culture supernatant allowing harvesting of the produced proteins. EGFR ligands, produced as FimH fusion proteins and released by proteolytic cleavage, bound to the EGF receptor (EGFR) on cancer cells inducing EGFR phosphorylation.
In another application of the technology, GLuc-FimH expressed on the surface of bacteria was used to track tumor-infiltrating bacteria by bioluminescence imaging upon application to mice, thereby visualizing the colonization of transplanted tumors. The examples indicate that the FimH-fusion protein technology can be used in various applications that require functionally active proteins to be displayed on bacterial surfaces or released into the culture supernatant.
fimh antibody cusabio
Introduction
Bacterial surface display of recombinant proteins has become an attractive strategy for a broad range of applications such as production of bioadsorbents1, generation of cellular biosensors, development of novel vaccine platforms3, screening of antibody libraries4 and whole-cell biocatalysis.
Generally, the procedure requires the fusion of the protein-of-interest (POI) to a bacterial surface protein to display the POI on the surface of the genetically modified bacteria. Several surface-anchoring motifs like LPP-OmpA, LamB, PhoE, ice nucleation protein (INP) and auto-transporter are employed as carrier proteins for crossing the bacteria membrane.
- Despite the successful approaches, several problems remain to be solved, including the substantially reduced functional activity of the displayed proteins. Compared with their soluble form, surface-anchored β-lactamase fused to the translation unit (TU) of an auto-transporter shows substantially reduced catalytic activities. A similar experience was made when displaying sorbitol dehydrogenase.
- A major problem in the use of auto-transporters arises from the tertiary structure of the passenger domains and the size of the central cavity that permits translocating only small proteins. It seems not only to be a matter of size since even the 62 amino acids protein aprotinin is not efficiently translocated through the outer membrane9.
- Translocation by auto-transporters is very sensitive to structure of the passenger proteins that consist of a β-strands backbone with at least 300 amino acids thereby substantially limiting the applicability to variety of potential cargos10.
- As an alternative approach, protein sequences derived from the major E. coli lipoprotein (Lpp) were fused to the N-terminus of the POI to direct the protein to the outer membrane11,12. The system consists of two key anchoring motifs; the Lpp-derived signal sequence at the N-terminus to target the fusion protein to the inner surface of the outer membrane, and the outer membrane protein A (OmpA)-derived transmembrane region to transfer the protein across the outer membrane12.
- Since its introduction by Ghrayeb and Inouye13 in 1984, the Lpp-OmpA display method is facing difficulties including the low expression rate and the insufficient translocation efficiency which may be due to steric hindrance and incorrect folding when anchoring in the outer membrane14,15.
- In Gram-negative bacteria the outer membrane generally acts as a barrier to restrict the protein export from the cell interior; only pilins, flagellins, specific surface enzymes, and a few bacterial toxins are transported across the outer membrane16.
- These natural display systems have the benefit of being optimized for transporting and folding protein units to build polymeric structures on the extracellular surface making the display system attractive for biotechnological applications. We here used the fimbriae protein FimH, the mannose-specific adhesin of the E. coli type-1 fimbriae, for the extracellular display of recombinant proteins.
- Type-1 fimbriae are composed of up to 3,000 copies of the subunit FimA, that form the pilus rod, as well as the subunits FimF, FimG and FimH building the distal tip fibrillum17,18. In initial studies, Pallesen and colleagues used the positions 225 and 258 within the FimH adhesin to display the preS2 domain of the hepatitis B surface antigen or an epitope from cholera toxin19.
- Both positions within the FimH protein proved to be suitable for the integration of peptides of up to 56 amino acids which could be produced, displayed on the cell surface and partially conserved the adhesive function of FimH19.
- Longer peptide or full length proteins displayed by FimH in that position were so far not reported. While short polypeptides used for vaccines could be displayed, the technique failed in functionally expressing large proteins like enzymes or cytokines.
- Here we identified alternative positions within the FimH protein to display larger proteins in a functionally active fashion. Based on the 3D modelling of E. coli type-1 pili20 we identified the N-terminus of the FimH domain on the fimbriae tip as a suitable integration site of a larger protein.
- As examples, we genetically linked Gaussia luciferase (GLuc) and human epidermal growth factor (EGF), tumor growth factor-a (TGF-α) and epiregulin (EREG), all ligands of the epidermal growth factor receptor (EGFR), to FimH.
- Expressed by transformed E. coli, the proteins conserved their functional capacities. In particular, GLuc-FimH displaying E. coli bacteria were tracked during colonization of syngeneic tumors in an immunocompetent mouse model of pancreatic cancer during a six week period without losing GLuc activity.
- Bacteria with surface displayed proteins can be used for screening purposes and, furthermore, can be released in a functionally active form by specific proteolytic cleavage making the strategy attractive for protein production without the need to disrupt the bacteria by harsh procedures.
 Recombinant E.coli Protein FimH Protein, His, Yeast-1mg |
| QP7372-ye-1mg | EnQuireBio | 1mg | EUR 3296.4 |
 Recombinant E.coli Protein FimH Protein, His, Yeast-200ug |
| QP7372-ye-200ug | EnQuireBio | 200ug | EUR 1512 |
 Recombinant E.coli Protein FimH Protein, His, Yeast-500ug |
| QP7372-ye-500ug | EnQuireBio | 500ug | EUR 2164.8 |
 Recombinant E.coli Protein FimH Protein, His, Yeast-50ug |
| QP7372-ye-50ug | EnQuireBio | 50ug | EUR 576 |
) Recombinant Escherichia coli FimH Protein (aa 22-300) |
| VAng-Lsx02377-1mgEcoli | Creative Biolabs | 1 mg (E. coli) | EUR 5751.6 |
Description: Escherichia coli protein FimH, recombinant protein. |
| Recombinant Escherichia coli FimH Protein (aa 22-300) |
| VAng-Lsx02377-500gEcoli | Creative Biolabs | 500 µg (E. coli) | EUR 3657.6 |
Description: Escherichia coli protein FimH, recombinant protein. |
| Recombinant Escherichia coli FimH Protein (aa 22-300) |
| VAng-Lsx02377-50gEcoli | Creative Biolabs | 50 µg (E. coli) | EUR 1083.6 |
Description: Escherichia coli protein FimH, recombinant protein. |
 Recombinant E.coli Protein FimH Protein, His-GST, E.coli-100ug |
| QP7372-ec-100ug | EnQuireBio | 100ug | EUR 848.4 |
 Recombinant E.coli Protein FimH Protein, His-GST, E.coli-10ug |
| QP7372-ec-10ug | EnQuireBio | 10ug | EUR 391.2 |
 Recombinant E.coli Protein FimH Protein, His-GST, E.coli-1mg |
| QP7372-ec-1mg | EnQuireBio | 1mg | EUR 2763.6 |
 Recombinant E.coli Protein FimH Protein, His-GST, E.coli-200ug |
| QP7372-ec-200ug | EnQuireBio | 200ug | EUR 1338 |
 Recombinant E.coli Protein FimH Protein, His-GST, E.coli-500ug |
| QP7372-ec-500ug | EnQuireBio | 500ug | EUR 1816.8 |
 Recombinant E.coli Protein FimH Protein, His-GST, E.coli-50ug |
| QP7372-ec-50ug | EnQuireBio | 50ug | EUR 522 |
) Escherichia coli Type 1 fimbrin D-mannose specific adhesin (fimH) |
| 1-CSB-EP362349ENV | Cusabio | - EUR 733.20
- EUR 370.80
- EUR 2192.40
- EUR 1126.80
- EUR 1461.60
- EUR 476.40
| - 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
- MW: 59.1 kDa
- Buffer composition: Tris-based buffer with 50% glycerol.
|
Description: Recombinant Escherichia coli Type 1 fimbrin D-mannose specific adhesin(fimH) expressed in E.coli |
| Escherichia coli Type 1 fimbrin D-mannose specific adhesin (fimH) |
| 1-CSB-EP362349ENVa0 | Cusabio | - EUR 733.20
- EUR 370.80
- EUR 2192.40
- EUR 1126.80
- EUR 1461.60
- EUR 476.40
| - 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
- MW: 33.1kDa
- Buffer composition: Tris-based buffer with 50% glycerol.
|
Description: Recombinant Escherichia coli Type 1 fimbrin D-mannose specific adhesin(fimH) expressed in E.coli |
| Escherichia coli Type 1 fimbrin D-mannose specific adhesin (fimH) |
| 1-CSB-EP362349ENVc7 | Cusabio | - EUR 733.20
- EUR 370.80
- EUR 2192.40
- EUR 1126.80
- EUR 1461.60
- EUR 476.40
| - 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
- MW: 29.8 kDa
- Buffer composition: Tris-based buffer with 50% glycerol.
|
Description: Recombinant Escherichia coli Type 1 fimbrin D-mannose specific adhesin(fimH) expressed in E.coli |
| Escherichia coli Type 1 fimbrin D-mannose specific adhesin (fimH) |
| 1-CSB-YP362349ENV | Cusabio | - EUR 814.80
- EUR 402.00
- EUR 2606.40
- EUR 1261.20
- EUR 1730.40
- EUR 522.00
| - 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
- MW: 31.1 kDa
- Buffer composition: Tris-based buffer with 50% glycerol.
|
Description: Recombinant Escherichia coli Type 1 fimbrin D-mannose specific adhesin(fimH) expressed in Yeast |
| Escherichia coli Type 1 fimbrin D-mannose specific adhesin (fimH) |
| 1-CSB-YP362349ENVe1 | Cusabio | - EUR 954.00
- EUR 541.20
- EUR 2745.60
- EUR 1400.40
- EUR 1869.60
- EUR 661.20
| - 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
- MW: 29.1 kDa
- Buffer composition: Tris-based buffer with 50% glycerol.
|
Description: Recombinant Escherichia coli Type 1 fimbrin D-mannose specific adhesin(fimH) expressed in Yeast |
 ASAP1 antibody Antibody |
| DF8746 | Affbiotech | 200ul | EUR 420 |
 anti- Antibody^Polyclonal antibody control antibody |
| LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
 ARHGDIA Antibody / RHOGDI Antibody |
| F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
| ARHGDIA Antibody / RHOGDI Antibody |
| F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
 Antibody) Anti-Glycolipid Antibody (AGA) Antibody |
| 20-abx004855 | Abbexa | - EUR 493.20
- EUR 710.40
- EUR 218.40
- EUR 376.80
| - 100 ul
- 200 ul
- 20 ul
- 50 ul
|
- Shipped within 5-10 working days.
|
 Antibody) Ly1 Antibody Reactive (LYAR) Antibody |
| 20-abx008109 | Abbexa | - EUR 360.00
- EUR 526.80
- EUR 226.80
| |
- Shipped within 5-10 working days.
|
| Ly1 Antibody Reactive (LYAR) Antibody |
| 20-abx123734 | Abbexa | | |
- Shipped within 5-10 working days.
|
| Ly1 Antibody Reactive (LYAR) Antibody |
| 20-abx014333 | Abbexa | - EUR 376.80
- EUR 117.60
- EUR 477.60
- EUR 594.00
| - 100 ug
- 10 ug
- 200 ug
- 300 µg
|
- Shipped within 5-10 working days.
|
| Ly1 Antibody Reactive (LYAR) Antibody |
| abx033330-400ul | Abbexa | 400 ul | EUR 627.6 |
- Shipped within 5-10 working days.
|
| Ly1 Antibody Reactive (LYAR) Antibody |
| abx033330-80l | Abbexa | 80 µl | EUR 343.2 |
- Shipped within 5-10 working days.
|
| Anti-Glycolipid Antibody (AGA) Antibody |
| abx036399-100ug | Abbexa | 100 ug | EUR 469.2 |
- Shipped within 5-10 working days.
|
 Antibody) Anti-Glycoprotein Antibody (GP) Antibody |
| 20-abx319900 | Abbexa | - EUR 493.20
- EUR 2214.00
- EUR 718.80
- EUR 218.40
- EUR 360.00
| - 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
- Shipped within 5-10 working days.
|
| Anti-Glycoprotein Antibody (GP) Antibody |
| 20-abx319901 | Abbexa | - EUR 493.20
- EUR 2214.00
- EUR 718.80
- EUR 218.40
- EUR 360.00
| - 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
- Shipped within 5-10 working days.
|
| Anti-Glycoprotein Antibody (GP) Antibody |
| 20-abx319905 | Abbexa | - EUR 493.20
- EUR 2214.00
- EUR 718.80
- EUR 218.40
- EUR 360.00
| - 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
- Shipped within 5-10 working days.
|
| Anti-Glycoprotein Antibody (GP) Antibody |
| 20-abx319913 | Abbexa | - EUR 493.20
- EUR 2214.00
- EUR 718.80
- EUR 218.40
- EUR 360.00
| - 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
- Shipped within 5-10 working days.
|
| Anti-Glycolipid Antibody (AGA) Antibody |
| abx230204-100ug | Abbexa | 100 ug | EUR 577.2 |
- Shipped within 5-12 working days.
|
| Ly1 Antibody Reactive (LYAR) Antibody |
| 20-abx324434 | Abbexa | | |
- Shipped within 5-10 working days.
|
| Ly1 Antibody Reactive (LYAR) Antibody |
| 20-abx311665 | Abbexa | - EUR 493.20
- EUR 2214.00
- EUR 718.80
- EUR 218.40
- EUR 360.00
| - 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
- Shipped within 5-10 working days.
|
| Ly1 Antibody Reactive (LYAR) Antibody |
| abx234901-100ug | Abbexa | 100 ug | EUR 661.2 |
- Shipped within 5-12 working days.
|
 Anti-Anti-SEPT6 antibody antibody |
| STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
 Anti-Anti-SEPT9 Antibody antibody |
| STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
 Anti-Anti-SEPT4 Antibody antibody |
| STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
 Anti-Anti-SEPT5 Antibody antibody |
| STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
CD11b Antibody Antibody
Antibody
Anti-Anti-SEPT11 Antibody antibody
Anti-Anti-MARCH9 Antibody antibody
Anti-Anti-MARCH8 Antibody antibody